Beta Drugs Limited — Investor Meet, 07-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Beta Drugs reported strong H1 FY’26. Revenue up 13% to ₹203.6 Cr, driven by 21% growth in domestic Own-brand and 40% in Cosmeceuticals. EBITDA hit ₹47.0 Cr (23.1% margin), PAT ₹28.7 Cr. International business gained 10%. Key wins include INVIMA-Colombia & COFEPRIS approvals, boosting global reach. Acquired oncology intermediate facility cuts import reliance, improves margins. Strategic focus: tier 2/3 expansion, new NDDS & high-end cosmeceutical launches, API export. Company shows solid operational execution and growth.